Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: ImmuCell Corporation

Market Cap 85.85M 74.86M 69.33M 64.9M 122M 8.1B 122M 822M 319M 3.99B 322M 315M 13.85B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 95.24M 83.04M 76.91M 72M 135M 8.99B 136M 912M 354M 4.42B 358M 350M 15.36B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.45%
Yield 2024 *
-
Yield 2025 -
1 day+1.12%
1 week-1.96%
Current month-7.32%
1 month-5.19%
3 months+56.34%
6 months+58.96%
Current year+54.31%
1 week 9.25
Extreme 9.25
9.58
1 month 9.25
Extreme 9.25
10.75
Current year 5.75
Extreme 5.75
10.75
1 year 4.52
Extreme 4.52
10.75
3 years 3.34
Extreme 3.34
10.75
5 years 3.34
Extreme 3.34
10.96
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer - 2025-10-31
Director of Finance/CFO 46 2025-04-06
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 2006-12-20
Director/Board Member 61 2014-03-30
Director/Board Member 66 2020-06-09
Date Insider Type Main position Quantity % Market Cap.
Apr. 14Free

Director

11,933 0.1319%
Apr. 14Free

Chairman

11,933 0.1319%
Apr. 14Other

Director

17,899 0.1979%
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%-1.96%+24.87%+65.62% 85.85M
-1.21%-3.04%+44.03%+142.51% 980B
-2.48%-5.18%+52.47%+39.36% 550B
-2.14%-4.94%+16.83%+58.18% 382B
+0.25%-3.09%+23.33%+16.78% 316B
+0.61%-1.69%+27.35%+14.22% 272B
+0.22%-3.10%+24.67%+30.69% 268B
+4.59%+1.98%-38.43%-46.41% 199B
-1.19%-4.95%+16.68%+48.70% 182B
-1.35%-1.46%+14.06%+59.46% 154B
Average -0.16%-2.97%+20.59%+42.91% 330.24B
Weighted average by Cap. -0.78%-3.68%+29.49%+63.49%

Financials

2024 2025
Net sales 26.49M 23.1M 21.39M 20.03M 37.56M 2.5B 37.79M 254M 98.36M 1.23B 99.45M 97.31M 4.27B 27.64M 24.1M 22.32M 20.9M 39.19M 2.61B 39.43M 265M 103M 1.28B 104M 102M 4.46B
Net income -2.16M -1.88M -1.74M -1.63M -3.06M -203M -3.08M -20.66M -8.01M -100M -8.1M -7.92M -348M -1.04M -907K -840K -786K -1.47M -98.13M -1.48M -9.96M -3.86M -48.3M -3.9M -3.82M -168M
Net Debt 11.34M 9.89M 9.16M 8.57M 16.08M 1.07B 16.18M 109M 42.11M 527M 42.57M 41.66M 1.83B 9.39M 8.19M 7.58M 7.1M 13.31M 886M 13.39M 89.93M 34.85M 436M 35.24M 34.48M 1.51B
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
26-06-18 9.490 $ +1.12% 34,226
26-06-17 9.385 $ +0.05% 29,398
26-06-16 9.380 $ -1.57% 14,092
26-06-15 9.530 $ -1.55% 9,740
  1. Stock Market
  2. Stocks
  3. ICCC Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!